Cancer Research Donn Young  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 1988, March 1, 2007. doi: 10.1158/0008-5472.CAN-06-3066
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, M.
Right arrow Articles by Zhang, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, M.
Right arrow Articles by Zhang, R.

Molecular Biology, Pathobiology, and Genetics

Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway

Mao Li1, Zhuo Zhang1, Donald L. Hill1,2, Hui Wang1,2 and Ruiwen Zhang1,2

1 Department of Pharmacology and Toxicology and 2 Division of Clinical Pharmacology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama

Requests for reprints: Ruiwen Zhang, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, VH 113, Box 600, 1670 University Boulevard, Birmingham, AL 35294. Phone: 205-934-8558; Fax: 205-975-9330; E-mail: ruiwen.zhang{at}ccc.uab.edu.

The oncoprotein MDM2, a major ubiquitin E3 ligase of tumor suppressor p53, has been suggested as a novel target for human cancer therapy based on its p53-dependent and p53-independent activities. We have identified curcumin, which has previously been shown to have anticancer activity, as an inhibitor of MDM2 expression. Curcumin down-regulates MDM2, independent of p53. In a human prostate cancer cell lines PC3 (p53null), curcumin reduced MDM2 protein and mRNA in a dose- and time-dependent manner, and enhanced the expression of the tumor suppressor p21Waf1/CIP1. The inhibitory effects occur at the transcriptional level and seem to involve the phosphatidylinositol 3-kinase/mammalian target of rapamycin/erythroblastosis virus transcription factor 2 pathway. Curcumin induced apoptosis and inhibited proliferation of PC3 cells in culture, but both MDM2 overexpression and knockdown reduced these effects. Curcumin also inhibited the growth of these cells and enhanced the cytotoxic effects of gemcitabine. When it was administered to tumor-bearing nude mice, curcumin inhibited growth of PC3 xenografts and enhanced the antitumor effects of gemcitabine and radiation. In these tumors, curcumin reduced the expression of MDM2. Down-regulation of the MDM2 oncogene by curcumin is a novel mechanism of action that may be essential for its chemopreventive and chemotherapeutic effects. Our observations help to elucidate the process by which mitogens up-regulate MDM2, independent of p53, and identify a mechanism by which curcumin functions as an anticancer agent. [Cancer Res 2007;67(5):1988–96]




This article has been cited by other articles:


Home page
Anticancer ResHome page
S. M. JOHNSON, P. GULHATI, I. ARRIETA, X. WANG, T. UCHIDA, T. GAO, and B. M. EVERS
Curcumin Inhibits Proliferation of Colorectal Carcinoma by Modulating Akt/mTOR Signaling
Anticancer Res, August 1, 2009; 29(8): 3185 - 3190.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A.R.M. R. Amin, O. Kucuk, F. R. Khuri, and D. M. Shin
Perspectives for Cancer Prevention With Natural Compounds
J. Clin. Oncol., June 1, 2009; 27(16): 2712 - 2725.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. S. Beevers, L. Chen, L. Liu, Y. Luo, N. J.G. Webster, and S. Huang
Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor Complex
Cancer Res., February 1, 2009; 69(3): 1000 - 1008.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Yu, G. Shen, T. O. Khor, J.-H. Kim, and A.-N. T. Kong
Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
Mol. Cancer Ther., September 1, 2008; 7(9): 2609 - 2620.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Z. Duan, E. J. Weinstein, D. Ji, R. Y. Ames, E. Choy, H. Mankin, and F. J. Hornicek
Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer
Mol. Cancer Ther., August 1, 2008; 7(8): 2377 - 2385.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Narasimhan and S. Ammanamanchi
Curcumin Blocks RON Tyrosine Kinase-Mediated Invasion of Breast Carcinoma Cells
Cancer Res., July 1, 2008; 68(13): 5185 - 5192.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B. Kunnumakkara, P. Diagaradjane, S. Guha, A. Deorukhkar, S. Shentu, B. B. Aggarwal, and S. Krishnan
Curcumin Sensitizes Human Colorectal Cancer Xenografts in Nude Mice to {gamma}-Radiation by Targeting Nuclear Factor-{kappa}B-Regulated Gene Products
Clin. Cancer Res., April 1, 2008; 14(7): 2128 - 2136.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.